adamantane has been researched along with niacinamide in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.17) | 29.6817 |
| 2010's | 29 (46.03) | 24.3611 |
| 2020's | 32 (50.79) | 2.80 |
| Authors | Studies |
|---|---|
| Raska, I; Toropov, AA; Toropova, AP | 1 |
| Adjei, AA; Bruzek, LM; Carter, CA; Gores, GJ; Kaufmann, SH; Meng, XW; Yu, C | 1 |
| Beljanski, V; Knaak, C; Smith, CD; Zhuang, Y | 1 |
| Anandan, SK; Chen, D; Gless, RD; MacIntyre, DE; Rubanyi, GM; Vincelette, J; Wang, YX; Webb, HK; Zhang, LN | 1 |
| Beljanski, V; Lewis, CS; Smith, CD | 1 |
| Baar, K; Carraway, KL; Gilda, JE; Gomes, AV; Hammock, BD; Hwang, SH; Leon, LJ; Patton, A; Wecksler, AT; Weiss, RH; Wettersten, HI | 1 |
| Mera, K; Nagasaka, Y; Oda, K; Tokoro, K | 1 |
| Akinlade, B; Ball, G; Catlin, M; Krueger, JG; Papp, K; Pariser, D; Wierz, G; Zeiher, B | 1 |
| Nakada, N; Oda, K | 1 |
| Cho, MH; Jang, JE; Kim, AR; Kim, BJ; Kim, H; Kim, HJ; Kim, JH; Kim, MO; Kim, SJ; Ko, MS; Koh, EH; Lee, KU; Leem, J; Oh, JS; Park, HS; Woo, CY; Yoo, HJ | 1 |
| Cao, YJ; Fisniku, O; Nagasaka, Y; Nakada, N; Oda, K; Sawamoto, T; Sohda, KY | 1 |
| Amore, E; Azzolina, A; Balasus, D; Bondì, ML; Botto, C; Cervello, M; Mazzaglia, A; Scala, A; Sortino, G | 1 |
| Ishikura, H; Iwasaki, M; Kaneko, Y; Saeki, S; Takeuchi, T; Tanaka, Y | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Boakye, J; Chaiteerakij, R; Chen, G; Ding, X; Huang, S; Li, Y; Moser, CD; Ndzengue, A; Roberts, LR; Shaleh, H; Sinicrope, FA; Smith, CD; Thomas, MB; Zhou, Y; Zou, X | 1 |
| Cao, YJ; Cho, K; Holman, J; Keirns, J; Lasseter, K; Lewand, M; Matson, M; Sawamoto, T; Swan, S; Valluri, U; Zhu, T | 1 |
| Garg, JP; Genovese, MC; Gutierrez-Ureña, SR; Kivitz, AJ; Kristy, R; Poiley, J; Shay, K; Wang, X; Zubrzycka-Sienkiewicz, A | 1 |
| Fisniku, O; Garg, JP; Han, D; Keirns, J; Nishimura, T; Parker, B; Wojtkowski, T; Zhu, T | 1 |
| Henter, ID; Lepow, L; Luckenbaugh, DA; Park, L; Zarate, CA | 1 |
| Chida, N; Higashi, Y; Inami, M; Inoue, T; Ito, M; Kuno, M; Morita, Y; Nakamura, K; Okuma, K; Shirakami, S; Yamagami, K; Yamazaki, S | 1 |
| Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A | 1 |
| Fisniku, O; Garg, JP; Han, D; Howieson, C; Keirns, J; Wojtkowski, T; Zhu, T | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Bertelsen, K; Feagan, BG; Johanns, J; Lichtenstein, GR; Marano, C; O'Brien, CD; Panes, J; Sandborn, WJ; Sands, BE; Strauss, R; Szapary, P; Vermeire, S; Yang, Z; Zhang, H | 1 |
| Amano, Y; Hamaguchi, H; Higashi, Y; Inoue, T; Ito, M; Moritomo, A; Nakai, K; Nakajima, Y; Nomura, N; Shirakami, S | 1 |
| Westhovens, R | 1 |
| Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S | 1 |
| Feng, Q; Guo, M; Qiu, Q; Tan, X | 1 |
| Keam, SJ; Markham, A | 1 |
| Iwasaki, M; Izutsu, H; Kaneko, Y; Katayama, K; Kawakami, A; Rokuda, M; Shiomi, T; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; van der Heijde, D; Yamada, E | 1 |
| Akazawa, R; Chen, YH; Iwasaki, M; Izutsu, H; Kaneko, Y; Kawakami, A; Lee, SH; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Wei, JC; Yamada, E | 1 |
| Lee, YH; Song, GG | 2 |
| Furihata, K; Kaneko, Y; Katashima, M; Miyatake, D; Nishimura, T; Oda, K; Sekino, H; Shibata, M; Shibata, T; Urae, A | 1 |
| Fujii, Y; Fukahori, H; Imamura, E; Kitanaga, Y; Kubo, S; Nakahara, Y; Nakayamada, S; Tanaka, Y | 1 |
| Furihata, K; Inoue, K; Ito, T; Kaneko, Y; Katashima, M; Miyatake, D; Nishimura, T; Oda, K; Sakaki, M; Shibata, T; Toyoshima, J; Uchida, N; Urae, A | 1 |
| Ferrante, M; Sabino, J | 1 |
| Georgiou, S; Plachouri, KM | 1 |
| Chen, YH; Izutsu, H; Kaneko, Y; Kawakami, A; Nakashima, Y; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Yamada, E | 1 |
| Hatta, T; Kaneko, Y; Nishimura, T; Oda, K; Saito, M; Shibata, M; Toyoshima, J | 1 |
| Izutsu, H; Tanaka, Y | 1 |
| Kaneko, Y; Nishimura, T; Oda, K; Shibata, M; Toyoshima, J | 1 |
| Gyu Song, G; Ho Lee, Y | 1 |
| Morinobu, A | 1 |
| Emori, T; Fujii, Y; Hashimoto, M; Higashi, Y; Ito, H; Kasahara, M; Narumiya, S; Sugahara, S | 1 |
| Akinlade, B; Cao, Y; Chindalore, V; Moy, S; Sawamoto, T; Valluri, U; Zhang, W; Zhu, T | 1 |
| Kambayashi, A; Kaneko, Y; Kiyota, T; Nishimura, T; Oda, K; Shibata, M; Toyoshima, J | 1 |
| Kaneko, Y | 1 |
| Abdel-Aal, RA; Abdel-Rahman, MS; Al Bayoumi, S; Ali, LA | 1 |
| Almengor-Montenegro, O; Amaya-Cabrera, EL; Cerpa-Cruz, S; González-Díaz, V; Gutiérrez-Ureña, SR; Martínez-Bonilla, GE; Rosal-Arteaga, C; Uribe-Martínez, JF; Ventura-Valenzuela, ME | 1 |
| Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Takeuchi, T; Tanaka, Y | 2 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Chen, C; Sun, C; Zhou, Y | 1 |
| Izutsu, H; Kaibara, A; Kaneko, Y; Nishimura, T; Shibata, M; Toyoshima, J | 1 |
| Fearon, U; Flynn, K; Hanlon, MM; Marzaioli, V; O'Brien, A; Veale, DJ; Wade, SC | 1 |
| Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Schultz, NM; Takeuchi, T; Tanaka, Y | 1 |
| Kim, JW; Kim, SY | 1 |
| Fukuda, M; Kaneko, Y; Kato, D; Miyatake, D; Takeuchi, T; Tanaka, Y | 1 |
| Emori, T; Fujii, Y; Hanaoka, K; Nakamura, Y; Nakano, M; Sugahara, S; Suzuki, T; Takahashi, J; Takeshita, N | 1 |
| Cai, C; Gao, X; He, X; Kaneko, Y; Kato, K; Miyatake, D; Oshima, H; Otsuka, Y; Shi, A; Song, N; Wojtkowski, T | 1 |
| Guo, L; Jiang, X; Wang, L; Zhang, L | 1 |
| Fujii, Y; Ishikawa, G; Kwon, C | 1 |
16 review(s) available for adamantane and niacinamide
| Article | Year |
|---|---|
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles | 2019 |
Peficitinib: First Global Approval.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Approval; Humans; Janus Kinases; Niacinamide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2019 |
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Dose-Response Relationship, Drug; Humans; Network Meta-Analysis; Niacinamide; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Efficacy of JAK inhibitors in Ulcerative Colitis.
Topics: Adamantane; Colitis, Ulcerative; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Niacinamide; Piperidines; Pyrimidines; Treatment Outcome | 2020 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Network Meta-Analysis; Niacinamide; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Heterocyclic Compounds, 3-Ring; Humans; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Triazoles | 2020 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
Efficacy and safety of peficitinib in rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Herpes Zoster; Humans; Janus Kinases; Niacinamide; Protein Kinase Inhibitors | 2020 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Niacinamide; Prednisolone | 2022 |
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Topics: Adamantane; Azetidines; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Janus Kinases; Network Meta-Analysis; Niacinamide; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Sulfonamides; Treatment Outcome | 2022 |
19 trial(s) available for adamantane and niacinamide
| Article | Year |
|---|---|
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
Topics: Adamantane; Biopsy; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Niacinamide; Psoriasis; Skin; Treatment Outcome | 2015 |
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinases; Japan; Male; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2016 |
Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.
Topics: Adamantane; Adolescent; Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Niacinamide; Young Adult | 2016 |
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2017 |
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
Topics: Adamantane; Administration, Oral; Adult; Drug Interactions; Female; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Janus Kinase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Niacinamide; Rosuvastatin Calcium; Young Adult | 2017 |
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Topics: Adamantane; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Janus Kinase 3; Male; Middle Aged; Niacinamide; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2017 |
The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
Topics: Adamantane; Administration, Oral; Adult; Anti-Arrhythmia Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Drug Interactions; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Niacinamide; Verapamil; Young Adult | 2017 |
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Topics: Adamantane; Administration, Oral; Adult; Biomarkers; C-Reactive Protein; Colitis, Ulcerative; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Intestinal Mucosa; Janus Kinase Inhibitors; Male; Middle Aged; Niacinamide; Quality of Life; Severity of Illness Index; Treatment Outcome | 2018 |
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Methotrexate; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Herpes Zoster; Humans; Janus Kinase Inhibitors; Japan; Male; Methotrexate; Middle Aged; Nasopharyngitis; Niacinamide; Republic of Korea; Severity of Illness Index; Taiwan; Treatment Outcome | 2020 |
Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Topics: Adamantane; Adult; Area Under Curve; Asian People; Double-Blind Method; Health Status; Healthy Volunteers; Humans; Japan; Male; Middle Aged; Niacinamide; Placebos; White People; Young Adult | 2020 |
A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Topics: Adamantane; Adult; Biological Transport; Drug Interactions; Healthy Volunteers; HEK293 Cells; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Male; Metformin; Niacinamide; Octamer Transcription Factor-1; Organic Cation Transport Proteins; Protein Kinase Inhibitors; Young Adult | 2020 |
Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Drug Interactions; Female; Half-Life; Humans; Male; Methotrexate; Middle Aged; Niacinamide | 2020 |
The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Topics: Adamantane; Administration, Oral; Adult; Area Under Curve; Arthritis, Rheumatoid; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Compounding; Drug Development; Fasting; Food; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Japan; Male; Niacinamide; Safety; Therapeutic Equivalency; Treatment Outcome | 2021 |
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Drug Tolerance; Female; Humans; Male; Middle Aged; Niacinamide; Treatment Outcome | 2021 |
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Humans; Methotrexate; Niacinamide; Patient Reported Outcome Measures; Physicians; Treatment Outcome | 2021 |
Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Middle Aged; Niacinamide; Treatment Outcome; Young Adult | 2022 |
Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects.
Topics: Adamantane; Administration, Oral; Area Under Curve; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Niacinamide | 2022 |
28 other study(ies) available for adamantane and niacinamide
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
Topics: Models, Molecular; Models, Statistical; Molecular Structure; Octanols; Quantitative Structure-Activity Relationship; Vitamins; Water | 2008 |
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
Topics: Adamantane; Apoptosis; Base Sequence; Benzenesulfonates; Caspases; Cell Line, Tumor; DNA Primers; Down-Regulation; Enzyme Activation; Humans; Hydroquinones; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2005 |
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
Topics: Adamantane; Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Caspase 3; Caspase 7; Catechols; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Humans; Kidney Neoplasms; Mice; Mice, SCID; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Topics: Adamantane; Administration, Oral; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Epoxide Hydrolases; Hypertension; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Niacinamide; Obesity; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Urea; Vasodilation | 2011 |
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Flow Cytometry; Hep G2 Cells; Humans; Liver Neoplasms; Lysophospholipids; Mice; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Sphingosine; Xenograft Model Antitumor Assays | 2011 |
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Autophagy; Benzamides; Caspases; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mitochondrial Membranes; Niacinamide; Oxidative Stress; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sorafenib; Urea | 2014 |
Simultaneous determination of a novel oral Janus kinase inhibitor ASP015K and its sulfated metabolite in rat plasma using LC-MS/MS.
Topics: Adamantane; Administration, Oral; Animals; Chromatography, Liquid; Female; Janus Kinases; Linear Models; Male; Niacinamide; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Sulfates; Tandem Mass Spectrometry | 2015 |
Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans.
Topics: Adamantane; Administration, Oral; Animals; Carbon Radioisotopes; Carbon-13 Magnetic Resonance Spectroscopy; Chimera; Chromatography, Liquid; Humans; Ions; Janus Kinases; Liver; Male; Mass Spectrometry; Metabolic Networks and Pathways; Metabolome; Metabolomics; Mice; Niacinamide; Protein Kinase Inhibitors; Proton Magnetic Resonance Spectroscopy; Rats, Sprague-Dawley | 2015 |
11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adamantane; Adiponectin; Adipose Tissue, White; Animals; Energy Metabolism; Enzyme Inhibitors; Gene Expression Regulation; Glycolysis; Hypertrophy; Lipid Metabolism; Lipotropic Agents; Liver; Male; Mice; Mice, Mutant Strains; Mitochondrial Dynamics; Niacinamide; Non-alcoholic Fatty Liver Disease; Obesity; Oxygen Consumption | 2015 |
Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor.
Topics: Adamantane; Administration, Oral; Adolescent; Adult; Carbon Radioisotopes; Feces; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Methylation; Middle Aged; Niacinamide; Nicotinamide N-Methyltransferase; Protein Kinase Inhibitors; Sulfotransferases; Young Adult | 2015 |
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells.
Topics: Adamantane; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Survival; Cyclodextrins; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Erythrocytes; Hemolysis; Hepatocytes; Humans; Kinetics; Nanostructures; Niacinamide; Phenylurea Compounds; Sorafenib; Surface-Active Agents | 2015 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Cells, Cultured | 2016 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Male; Memantine; Middle Aged; Niacinamide; Predictive Value of Tests; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2017 |
A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
Topics: Adamantane; Adjuvants, Immunologic; Administration, Oral; Animals; Arthritis, Experimental; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; Infusions, Parenteral; Janus Kinase 1; Janus Kinase 3; Male; Niacinamide; Phosphorylation; Rats; STAT5 Transcription Factor; T-Lymphocytes | 2017 |
Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
Topics: Adamantane; Administration, Oral; Animals; Arthritis, Rheumatoid; Biological Availability; Drug Discovery; Humans; Janus Kinase Inhibitors; Mice; Niacinamide; Rats; Structure-Activity Relationship | 2018 |
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane | 2019 |
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Topics: Adamantane; Administration, Oral; Adult; Aged; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Niacinamide; Renal Insufficiency; Young Adult | 2020 |
In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
Topics: Adamantane; Arthritis, Rheumatoid; Female; Humans; Janus Kinase Inhibitors; Lymphocyte Activation; Lymphocytes; Male; Niacinamide; Phosphorylation; Scleroderma, Systemic; STAT Transcription Factors | 2020 |
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Topics: Adamantane; Administration, Oral; Aged; Area Under Curve; Asian People; Female; Humans; Janus Kinase Inhibitors; Liver Diseases; Liver Function Tests; Male; Middle Aged; Niacinamide; Severity of Illness Index | 2020 |
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Niacinamide | 2020 |
Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Topics: Adamantane; Apoptosis; Arthritis, Rheumatoid; Azetidines; Cells, Cultured; Cytokines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Phosphorylation; Piperidines; Purines; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Synoviocytes | 2020 |
Effect of stevia aqueous extract on the antidiabetic activity of saxagliptin in diabetic rats.
Topics: Adamantane; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptides; Herb-Drug Interactions; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Niacinamide; Plant Extracts; Rats; Rats, Wistar; Stevia; Streptozocin | 2021 |
Peficitinib hydrobromide to treat rheumatoid arthritis.
Topics: Adamantane; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Janus Kinases; Niacinamide; Treatment Outcome | 2020 |
The optimal dosage of pefcitinib for the treatment of active rheumatoid arthritis: A protocol for an updated network meta-analysis.
Topics: Adamantane; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Network Meta-Analysis; Niacinamide; Research Design | 2021 |
Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Biological; Niacinamide; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |
Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
Topics: Adamantane; Adult; Aged; Arthritis, Psoriatic; Azetidines; Cells, Cultured; Female; Fibroblasts; Heterocyclic Compounds, 3-Ring; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Male; Middle Aged; Niacinamide; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Synovial Membrane; Triazoles | 2021 |
Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice.
Topics: Adamantane; Animals; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Disease Models, Animal; Janus Kinase Inhibitors; Male; Mice, Inbred DBA; Niacinamide; Osteoblasts; Osteoporosis; RANK Ligand | 2022 |
Peficitinib inhibits fibroblast-like synoviocyte activation and angiogenic vascular endothelial tube formation via inhibitory effects on PDGF and VEGF signaling in addition to JAK.
Topics: Adamantane; Arthritis, Rheumatoid; Cells, Cultured; Fibroblasts; Human Umbilical Vein Endothelial Cells; Humans; Janus Kinases; Niacinamide; Platelet-Derived Growth Factor; Signal Transduction; Synoviocytes; Tyrosine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2022 |